Paragonix Technologies, Inc. today announced that the European Society for Organ Transplantation (ESOT) accepted for presentation an abstract describing the performance of the Sherpa Pak™ Cardiac Transport System during the upcoming 16th Congress of the European Society for Organ Transplantation to be held in Vienna, Austria from the 8th - 11th September 2013.
“Cardiac transplantation continues to be the gold standard for the treatment of end-stage heart failure. However, the number of potential transplants far exceeds the number of donors.”
Lisa M. Anderson, PhD, Chief Operating Officer and Co-Founder for Paragonix commented, "We are excited to present the Sherpa Pak™ Cardiac Transport System during the ESOT Congress. We look forward to future presentations in clinical forums discussing the exceptional organ transportation characteristics of the Paragonix Sherpa™."
Dr. Steven Tsui, MA, MD, FRCS, co-author on the abstract and the Director of the Transplant & Mechanical Circulatory Support program at Papworth Hospital, University of Cambridge, UK, commented, "The ESOT is a world-class forum where clinicians can meet and discuss challenges facing the organ transplantation community. The Sherpa Pak™ Cardiac Transport System represents an innovative approach to heart storage and transportation. I look forward to a stimulating discussion with my colleagues during the Congress."
Previous Announcements
Paragonix previously announced on February 12, 2013, Clearance of a 510(k) Pre-Marketing Notification Application with the US Food and Drug Administration for the Paragonix Sherpa™ Cardiac Transport System.
Paragonix previously announced on November 6, 2012, filing of a 510(k) Pre-Marketing Notification Application with the US Food and Drug Administration for the Paragonix Sherpa™ Cardiac Transport System.
Paragonix previously announced on July 16, 2012, award of a Phase I Small Business Innovation Research (SBIR) Grant to support the pre-clinical development of the Paragonix Sherpa™ Cardiac Transport in collaboration with the Transplant Center at Massachusetts General Hospital (Boston).
Paragonix previously announced on June 25, 2012, Appointment of Leonard A. R. Golding, MB, BS, FRACS, FRCS(C), FACC as Chief Medical Officer.
Paragonix previously announced on June 18, 2012, Formation of a Clinical Advisory Board for the Paragonix Sherpa™ Cardiac Transport System.
Regular use of fish oil supplements linked to increased heart disease risk in healthy individuals